AUTHOR=Fernandes Messias Márcia Cristina , Mecatti Giovana Colozza , Figueiredo Angolini Célio Fernando , Eberlin Marcos Nogueira , Credidio Laura , Real Martinez Carlos Augusto , Rodrigues Coy Cláudio Saddy , de Oliveira Carvalho Patrícia 

TITLE=Plasma Lipidomic Signature of Rectal Adenocarcinoma Reveals Potential Biomarkers

JOURNAL=Frontiers in Oncology

VOLUME=Volume 7 - 2017

YEAR=2018

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2017.00325

DOI=10.3389/fonc.2017.00325

ISSN=2234-943X

ABSTRACT=Background: Rectal adenocarcinoma (RAC) is a common malignant tumor of the digestive tract with a high incidence and high mortality. Lipidomic strategy can be used to identify potential biomarkers for establishing early diagnosis or therapeutic programs for RAC. Objective: To evaluate the lipoperoxidation biomarkers and lipidomic signature in the plasma of patients with RAC (n=23) and healthy controls (n=18). Methods: Lipoperoxidation was evaluated based on malondialdehyde (MDA) and F2-isoprostane levels and the lipidomic profile obtained by gas chromatography (GC) and high resolution mass spectrometry (ESI-q-TOF) associated with a multivariate statistical technique. Results: The most abundant ions identified in the RAC patients were those of protonated phosphatidylcholine (PC) and phosphatidylethanolamine (PE). It was found that a lisophosphatidylcholine plasmalogen containing palmitoleic acid (LPC (P-16:1)), with highest variable importance projection score, showed a tendency to be lower in the cancer patients. A reduction of n-3 polyunsaturated fatty acids (PUFA) was observed in the plasma of these patients. MDA levels were higher in patients with advanced cancer (stages III/IV) than in the early stages groups and the healthy group (p<0.05). No differences in F2-isoprostane levels were observed among these groups. Conclusion: This study shows that the reduction in plasma levels of LPC plasmalogens associated to an increase in MDA levels may indicate increased oxidative stress in these patients and identify the metabolite LPC (P-16:1) as a putatively novel lipid signature for RAC.